A recent study evaluated the effects of a moisturizer containing 20% urea on patients with keratosis pilaris (KP) and found that it may help to improve the skin’s smoothness and
In a recent press release, Galderma announced that RelabotulinumtoxinA significantly improved glabellar and lateral canthal lines. Data from their Phase III READY-3 clinical trial reveal that a single dose of
According to a recent phase 2a randomized clinical trial, PF-07038124, a topical PDE4 inhibitor, is an effective and well-tolerated treatment for patients with atopic dermatitis (AD) and plaque psoriasis. “Topical
The U.S. Food and Drug Administration (FDA) has approved ZELSUVMIâ„¢ (berdazimer topical gel, 10.3%) from Ligand Pharmaceuticals Incorporated for the treatment of molluscum contagiosum in adults and pediatric patients aged
On December 19, Chiesi Global Rare Diseases announced that the U.S. Food and Drug Administration (FDA) approved FILSUVEZ® (birch triterpenes), a topical gel for the treatment of partial thickness wounds
Arcutis Biotherapeutics recently announced that the U.S. Food and Drug Administration (FDA) approved their new drug application for ZORYVE® (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in
The U.S. Food and Drug Administration (FDA) recently issued a notification to isotretinoin manufacturers to state that they must modify the iPledge Risk Evaluation and Mitigation Strategy (REMS). Originally implemented
Dermavant Sciences recently announced positive results from their phase 4 open-label clinical trial of VTAMA® (tapinarof) cream 1% for the treatment of plaque psoriasis in the head and neck region
Biopharmaceutical company, Almirall, recently announced in a press release that the European Commission (EC) has granted approval for EBGLYSSⓇ (lebrikizumab) for moderate-to-severe atopic dermatitis (AD) in patients 12 years and
The treatment and management of vitiligo can be challenging for both patients and their providers. Vitiligo carries a significant disease burden, both physically and mentally. Furthermore, due to the lack
A recent study published in the Journal of the American Academy of Dermatology sought to evaluate the prevalence of allergic contact dermatitis (ACD) in children with atopic dermatitis (AD). According
Hyperhidrosis (HH) is a condition characterized by excessive sweating beyond what is necessary for thermoregulation and affects millions of people worldwide. It can be a debilitating condition, often causing social
Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults. Cosentyx is the first interleukin-17A
Bausch Health has announced that the U.S. Food and Drug Administration (FDA) has approved IDP-126 (Cabtreoâ„¢) for the treatment of acne in patients aged 12 years and older. IDP-126 (clindamycin
The U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is
AbbVie recently announced that its phase 2b study evaluating upadacitinib (RINVOQ®) for the treatment of adults with nonsegmental vitiligo (NSV) met the primary endpoint of percent change from baseline in
Arcutis Biotherapeutics recently announced that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) for the expanded indication of ZORYVE (roflumilast) cream 0.3% for the
Kenvue recently revealed that an over-the-counter (OTC) moisturizer containing 1% colloidal oatmeal was shown to be effective in improving Eczema Area and Severity Index (EASI) scores in Black children. Colloidal
In a recent study, researchers aimed to characterize somatosensory profiles in patients with hidradenitis suppurativa (HS) at clinically affected and nonaffected areas compared with pain-free reference data. They noted that
Arcutis Biotherapeutics recently announced the interim results of its phase 3, long-term extension trial of roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children 6
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
